Addressing Unmet Patient Needs in Retinal Therapeutics
Drive Therapeutics, LLC is a new biotechnology company that strives to improve treatment for retinal diseases. Founded in the heart of RTP, NC in 2019, the company will use its patent protected assets to develop therapeutics for wet age-related macular degeneration (wAMD) and diabetic retinopathy/diabetic macular edema (DR/DME). In addition to current candidates, our platform technology will allow for streamlined, efficient development of new therapies to pathologically relevant targets.
Our Innovative Technology
The Possibilities Are Endless
Retinal diseases, including wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) affect over 2.2 million Americans. The treatment for both retinal diseases is the same and has been revolutionized by the advent of anti-VEGF therapy, which has come to dominate the market. While anti-VEGF therapies improve many patients’ lives, a significantly large portion of patients do not respond or fully benefit from treatment (~50% in the case of DME and 25-75%, in the case of wAMD). Drive Therapeutics, LLC, has developed stable, non-immunogenic, candidate molecules that inhibit novel targets in the progression of retinal disease. These molecules can be used by themselves, in conjunction with each other, or combined with existing therapies to achieve greater therapeutic efficacy while reducing the dosing regimen, resulting in better patient outcome.
"Nothing great was ever achieved without enthusiasm"